Health

From Bangkok to the World: Aura Bangkok Clinic Showcases International Standards in Aesthetic Care

BANGKOK, Nov. 11, 2025 /PRNewswire/ -- Aura Bangkok Clinic, a leader in Thailand's medical aesthetic industry, is enhancing the country's reputation as a top destination for Thai beauty medical tourism through its global expertise, award-winning services, and internationally recognized training p...

2025-11-11 22:00 1261

Mabwell's Novel Anti‑IL‑11 Monoclonal Antibody 9MW3811 Approved by NMPA to Initiate Phase II Clinical Trial in Pathological Scarring

SHANGHAI, Nov. 11, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that its novel anti‑IL‑11 monoclonal antibody 9MW3811 has received approval from the China National Medical Products Administration (NMPA) to initiate...

2025-11-11 22:00 1644

Coreline Soft Selected as Exclusive AI Provider for France's National Lung Cancer Screening Pilot Project, IMPULSION

- APHP-led IMPULSION project secures Coreline Soft as sole AI supplier - UGAP (France's central public procurement agency) registration completed, opening opportunities withFrance's largest public hospitals SEOUL, South Korea, Nov. 11, 2025 /PRNewswire/ -- Coreline Soft

2025-11-11 21:00 1130

MGI Tech Joins Forces with SAMRC and DSTI to Launch South Africa's 110K Human Genome Program and Unveil Africa's First DNBSEQ-T7, Ushering a New Era in African Genomics

CAPE TOWN, South Africa, Nov. 11, 2025 /PRNewswire/ -- MGI Tech Co., Ltd., a company dedicated to developing core tools and technologies that drive innovation in life sciences, today announced two historic milestones in African genomics: the official unveiling of the continent's first DNBSEQ-T7 s...

2025-11-11 17:40 1149

LiberNovo Launches Black Friday Savings: Redefine Your Workspace for Health

HONG KONG, Nov. 10, 2025 /PRNewswire/ -- The season for serious deals has arrived, and LiberNovo today launched its Black Friday & Cyber Monday (BFCM) sale across across the U.S. and Canada—with limited-time discounts of up to 34% on its flagship product,the LiberNovo Omni

2025-11-11 00:00 2448

Tiumbio to Present First Clinical Data for Dual TGF-β/VEGF Inhibitor Tosposertib (TU2218) at SITC 2025, "Robust Response Rate"

* 70.6% Partial Response and 82.4% Disease Control Rate Observed in Interim Phase II Data SEONGNAM, South Korea, Nov. 10, 2025 /PRNewswire/ -- On Friday, 7 November (local time) at the Society for Immunotherapy of Cancer (SITC) 2025 annual meeting, Tiumbio Co., Ltd. (KOSDAQ: 321550), a clinical...

2025-11-10 21:00 1463

Fapon to Showcase Innovative Molecular Diagnostic Solutions at AMP 2025 Annual Meeting & Expo

BOSTON, Nov. 10, 2025 /PRNewswire/ -- Fapon, a globally leading life sciences organization, will exhibit at the AMP 2025 Annual Meeting & Expo duringNovember 11-15 in Boston, presenting its cutting-edge enzymes for molecular diagnostics that power qPCR/RT-qPCR, Isothermal Amplification, and Next-...

2025-11-10 20:30 1121

Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage

NANJING, China, Nov. 10, 2025 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK) announced that its regulatory T cells(Treg)-preferential IL-2 mutant Fc fusion protein (IL-2 mu-Fc), SIM0278, has officially entered a Phase II clinical study inChina for the treatment of moderate-to-severe atopi...

2025-11-10 20:06 1431

Origin Agritech Strengthens Gene Editing Platform through Patent License Agreement with Shunfeng BioTech

BEIJING, Nov. 10, 2025 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, today announced it has entered into a patent license agreement with Shandong Shunfeng Biotechnology Co., Ltd. ("Shunfeng BioTech") for the Cas...

2025-11-10 20:00 1436

LISCure Biosciences Initiates Global Phase 2 Trial of LB-P8 in Primary Sclerosing Cholangitis (PSC)

SEOUL, South Korea, Nov. 10, 2025 /PRNewswire/ -- LISCure Biosciences  ("LISCure"), a clinical-stage biopharmaceutical company, announced the initiation of patient dosing in aglobal Phase 2 clinical trial of LB-P8, a novel therapeutic candidate for Primary Sclerosing Ch...

2025-11-10 20:00 1065

Akeso Announces First Patient Dosed in Phase I Trial of Personalized mRNA Vaccine AK154 as Monotherapy or in Combination with Cadonilimab or Ivonescimab for Adjuvant Treatment of Pancreatic Cancer

HONG KONG, Nov. 10, 2025 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926. HK) is pleased to announce that the first patient has been dosed in a Phase I clinical trial evaluating the personalized mRNA vaccine AK154. This trial is investigating AK154 both as a monotherapy and as a combination with the com...

2025-11-10 19:39 1112

SanegeneBio Announces RNAi Licensing and Research Collaboration with Lilly

-Companies will collaborate on RNAi research for metabolic disease targets BOSTON, Nov. 8, 2025 /PRNewswire/ -- SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced a global research and licensing collaboration with Eli Lilly and Company ("...

2025-11-08 18:00 1486

Get Ready for the Holidays as VARON Launches Black Friday Early Access Savings on Oxygen Concentrators

NEW YORK, Nov. 7, 2025 /PRNewswire/ -- As the holiday season approaches, one essential product that continues to improve lives is the oxygen concentrator. For individuals living with chronic respiratory conditions, having reliable access tosupplemental oxygen

2025-11-07 23:31 1716

Lunit AI Maps the Tumor-Immune Landscape to Predict Immunotherapy Response and Discover New Antibody Targets at SITC 2025

Studies reveal how the Lunit SCOPE® suite identifies immunotherapy-responsive subtypes, standardizes immune phenotyping, and accelerates antibody-based target discovery SEOUL, South Korea, Nov. 7, 2025 /PRNewswire/ -- Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precis...

2025-11-07 22:05 3065

HanchorBio Presents Two Late-Breaking Abstracts at the Society for Immunotherapy of Cancer 2025 Demonstrating Best-in-Class Potential of HCB101 in Advanced Cancers

Late-breaking poster presentations show HCB101's favorable safety, strong receptor occupancy, and promising monotherapy and combination activity in tumors historically unresponsive to immunotherapy TAIPEI, SHANGHAI, and SAN FRANCISCO, Nov. 7, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827), a ...

2025-11-07 22:00 3067

'Coffee Diplomacy' at APEC: Korea-U.S. Startup Imunika Goes Viral as Japan's Motegi Prepares Tariff Talks with Trump

Japan's newly appointed Foreign Minister Toshimitsu Motegi sparked an unexpected viral moment at APEC 2025 after stopping by Imunika — the official coffee sponsor of APEC 2025 Korea, a Korea–U.S. startup redefining "Wellness Specialty Coffee." SEOUL, South Korea and WASHINGTON, Nov. 7, 2025 /PRN...

2025-11-07 21:00 1458

Coreline Soft Unveils AVIEW 2.0 at RSNA 2025: Next-Generation AI Platform Redefining Radiology Workflow Standards

CHICAGO and SEOUL, South Korea, Nov. 7, 2025 /PRNewswire/ -- Coreline Soft  will introduce its groundbreaking chest AI platform AVIEW 2.0 at RSNA 2025 (November 30–December 4, Chicago), demonstrating how unified AI automation is fundamentally trans...

2025-11-07 21:00 1604

Alebund Presents Phase 3 Trial Results of AP301 at the American Society of Nephrology (ASN) 2025 Congress

* Clinically and statistically significant superiority of AP301 maintenance dose versus ineffective low dose in reducing serum phosphate levels was established and AP301's efficacy is sustained throughout the 52 weeks of treatment. * The non-inferiority of AP301 to sevelamer carbonate in redu...

2025-11-07 20:00 1376

Smartee Celebrates the Opening of its 4.0 Digital Orthodontic Technology Exhibition Hall in Jiaxing, China

JIAXING, China, Nov. 7, 2025 /PRNewswire/ -- Smartee Denti-Technology has unveiled the Smartee Digital Orthodontic Technology Exhibition Hall, a 1,200-square-meter space dedicated to showcasing the company's innovations in clear aligner therapy and digital orthodontics. The event gathered a dist...

2025-11-07 18:05 1466

Harbour BioMed and Evinova China Announce Strategic AI Collaboration to Accelerate AI-Enabled Drug Development

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 7, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, andEvinova, a global ...

2025-11-07 14:00 1575
1 ... 15161718192021 ... 317